Tue, Mar 01
|Virtual/Live
Kicking Cancer's KRAS Expert Series with Dr. Tanios Bekaii-Saab
Tanios Bekaii-Saab, M.D., FACP, Leader of the Gastrointestinal Cancer Program, and Director of the Clinical Cancer Research Office for the Enterprise wide Mayo Clinic Cancer Center will be joining us to discuss the latest in research and treatments for patients with gastrointestinal cancers.
Time & Location
Mar 01, 2022, 2:30 PM – 4:00 PM EST
Virtual/Live
About the Event
We are very excited to welcome Tanios Bekaii-Saab, M.D., FACP, to the Kicking Cancer's KRAS Expert Series! Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program, and Director of the Clinical Cancer Research Office for the Enterprise wide Mayo Clinic Cancer Center. He is also the Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA.
Dr. Bekaii-Saab conducts clinical and translational research focused on developing anticancer agents for patients with gastrointestinal cancers. He collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. His research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. Additionally, Dr. Bekaii-Saab’s research has also led to the launch of a number of phase II and III clinical trials, including but not limited to a recent trial with a cancer stem cell inhibitor in pancreatic cancer, the development of an FGFR inhibitor in bile duct cancers including a contribution to the regulatory approval of infigratinib and pemigatinib.
Learn more about Dr. Bekaii-Saab here.